Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for InflaRx N.V. (IFRX : NSDQ)
 
 • Company Description   
InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

Number of Employees: 59

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.50 Daily Weekly Monthly
20 Day Moving Average: 120,439 shares
Shares Outstanding: 44.20 (millions)
Market Capitalization: $66.31 (millions)
Beta: 0.82
52 Week High: $5.69
52 Week Low: $1.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.73% -5.08%
12 Week -51.77% -46.97%
Year To Date -68.49% -61.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
WINZERLAER STR. 2
-
JENA,2M 07745
DEU
ph: 49-36-4150-8180
fax: -
jordan.zwick@inflarx.de http://www.inflarx.de
 
 • General Corporate Information   
Officers
Niels Riedemann - Executive Director and Chief Executive Officer
Nicolas Fulpius - Chairman
Thomas Taapken - Chief Financial Officer
Richard Brudnick - Director
Mark Kubler - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N44821101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 44.20
Most Recent Split Date: (:1)
Beta: 0.82
Market Capitalization: $66.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.62
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -63.64%
vs. Previous Quarter: -9.09%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -48.22
12/31/21 - -37.38
09/30/21 - -36.94
ROA
03/31/22 - -42.01
12/31/21 - -33.64
09/30/21 - -33.68
Current Ratio
03/31/22 - 5.47
12/31/21 - 5.10
09/30/21 - 7.74
Quick Ratio
03/31/22 - 5.47
12/31/21 - 5.10
09/30/21 - 7.74
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.41
12/31/21 - 2.82
09/30/21 - 3.14
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©